Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1989 Mar;86(5):1643–1647. doi: 10.1073/pnas.86.5.1643

Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.

B Szende 1, A Zalatnai 1, A V Schally 1
PMCID: PMC286755  PMID: 2564204

Abstract

Female Syrian golden hamsters with N-nitrosobis(2-oxopropyl)amine (BOP)-induced ductal pancreatic cancers were treated with long-acting microcapsular preparations of the 6-D-tryptophan analog of luteinizing hormone-releasing hormone [( D-Trp6]LH-RH), releasing 25 micrograms/day; the somatostatin analog D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 (RC-160), liberating 15 micrograms/day; and the combination of these two peptides. Therapy with analogs was initiated 24 weeks after initial administration of BOP. These treatments resulted in significantly better survival of all animals as compared to BOP controls; body weights of surviving peptide-treated animals were significantly higher than those of the BOP controls. All 15 BOP-control animals had pancreatic cancers. In the group treated with RC-160 four hamsters were free of tumors, whereas therapy with [D-Trp6]LH-RH resulted in seven tumor-free animals, and combination of RC-160 and [D-Trp6]LH-RH resulted in eight tumor-free animals from groups of 15. Only preblastomatous lesions were found in these animals. Average tumor weight of animals in all peptide-treated groups, sacrificed 60 days after beginning the peptide treatment, was significantly lower than that of BOP controls. No significant differences were seen between the various peptide-treated groups. Histologically, analog-treated tumors of hamsters showed striking regressive changes characteristic of programmed cell death (apoptosis). This apoptosis presumably resulted from hormonal effects on tumor cells from prolonged treatment with these analogs of hypothalamic hormones. Our present data confirm the beneficial effect of long-acting microcapsules of [D-Trp6]LH-RH and RC-160 on pancreatic carcinoma and suggest a mode of action for these peptides. The feasibility of applying this treatment with analogs of hypothalamic hormones to human pancreatic carcinoma can be envisioned from these studies.

Full text

PDF
1643

Images in this article

1644Image
on p.1644
1645Image
on p.1645
1645Image
on p.1645
1645Image
on p.1645
1645Image
on p.1645

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benz C., Hollander C., Miller B. Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res. 1986 May;46(5):2276–2281. [PubMed] [Google Scholar]
  2. Cai R. Z., Szoke B., Lu R., Fu D., Redding T. W., Schally A. V. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1896–1900. doi: 10.1073/pnas.83.6.1896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Corbishley T. P., Iqbal M. J., Wilkinson M. L., Williams R. Androgen receptor in human normal and malignant pancreatic tissue and cell lines. Cancer. 1986 May 15;57(10):1992–1995. doi: 10.1002/1097-0142(19860515)57:10<1992::aid-cncr2820571019>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  4. Crass R. A., Morgan R. G. The effect of long-term feeding of soya-bean flour diets on pancreatic growth in the rat. Br J Nutr. 1982 Jan;47(1):119–129. doi: 10.1079/bjn19820017. [DOI] [PubMed] [Google Scholar]
  5. Gold E. B., Gordis L., Diener M. D., Seltser R., Boitnott J. K., Bynum T. E., Hutcheon D. F. Diet and other risk factors for cancer of the pancreas. Cancer. 1985 Jan 15;55(2):460–467. doi: 10.1002/1097-0142(19850115)55:2<460::aid-cncr2820550229>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  6. Gonzalez-Barcena D., Rangel-Garcia N. E., Perez-Sanchez P. L., Gutierrez-Damperio C., Garcia-Carrasco F., Comaru-Schally A. M., Schally A. V. Response to D-Trp-6-LH-RH in advanced adenocarcinoma of pancreas. Lancet. 1986 Jul 19;2(8499):154–154. doi: 10.1016/s0140-6736(86)91961-6. [DOI] [PubMed] [Google Scholar]
  7. Greenway B. A. Carcinoma of the exocrine pancreas: a sex hormone responsive tumour? Br J Surg. 1987 Jun;74(6):441–442. doi: 10.1002/bjs.1800740602. [DOI] [PubMed] [Google Scholar]
  8. Greenway B., Duke D., Pym B., Iqbal M. J., Johnson P. J., Williams R. The control of human pancreatic adenocarcinoma xenografts in nude mice by hormone therapy. Br J Surg. 1982 Oct;69(10):595–597. doi: 10.1002/bjs.1800691013. [DOI] [PubMed] [Google Scholar]
  9. Hierowski M. T., Liebow C., du Sapin K., Schally A. V. Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS Lett. 1985 Jan 7;179(2):252–256. doi: 10.1016/0014-5793(85)80529-9. [DOI] [PubMed] [Google Scholar]
  10. Howatson A. G., Carter D. C. Pancreatic carcinogenesis-enhancement by cholecystokinin in the hamster-nitrosamine model. Br J Cancer. 1985 Jan;51(1):107–114. doi: 10.1038/bjc.1985.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Howatson A. G., Carter D. C. Pancreatic carcinogenesis: effect of secretin in the hamster- nitrosamine model. J Natl Cancer Inst. 1987 Jan;78(1):101–105. doi: 10.1093/jnci/78.1.101. [DOI] [PubMed] [Google Scholar]
  12. Johnson L. R. Effects of gastrointestinal hormones on pancreatic growth. Cancer. 1981 Mar 15;47(6 Suppl):1640–1645. doi: 10.1002/1097-0142(19810315)47:6+<1640::aid-cncr2820471430>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  13. Kerr J. F., Wyllie A. H., Currie A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972 Aug;26(4):239–257. doi: 10.1038/bjc.1972.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Konturek S. J., Bilski J., Jaworek J., Tasler J., Schally A. V. Comparison of somatostatin and its highly potent hexa- and octapeptide analogs on exocrine and endocrine pancreatic secretion. Proc Soc Exp Biol Med. 1988 Feb;187(2):241–249. doi: 10.3181/00379727-187-42661. [DOI] [PubMed] [Google Scholar]
  15. Liebow C., Hierowski M., duSapin K. Hormonal control of pancreatic cancer growth. Pancreas. 1986;1(1):44–48. doi: 10.1097/00006676-198601000-00009. [DOI] [PubMed] [Google Scholar]
  16. Malt R. A. Treatment of pancreatic cancer. JAMA. 1983 Sep 16;250(11):1433–1437. [PubMed] [Google Scholar]
  17. Oates P. S., Bruce N. W., Morgan R. G. Pancreatic blood flow in the rat during enlargement, involution, and cholecystokinin treatment. Am J Physiol. 1984 Nov;247(5 Pt 1):G457–G462. doi: 10.1152/ajpgi.1984.247.5.G457. [DOI] [PubMed] [Google Scholar]
  18. Paz-Bouza J. I., Redding T. W., Schally A. V. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1987 Feb;84(4):1112–1116. doi: 10.1073/pnas.84.4.1112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pour P., Althoff J., Takahashi M. Early lesions of pancreatic ductal carcinoma in the hamster model. Am J Pathol. 1977 Aug;88(2):291–308. [PMC free article] [PubMed] [Google Scholar]
  20. Redding T. W., Schally A. V. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci U S A. 1984 Jan;81(1):248–252. doi: 10.1073/pnas.81.1.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Schally A. V., Comaru-Schally A. M., Redding T. W. Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med. 1984 Mar;175(3):259–281. doi: 10.3181/00379727-175-41797. [DOI] [PubMed] [Google Scholar]
  22. Schally A. V. Oncological applications of somatostatin analogues. Cancer Res. 1988 Dec 15;48(24 Pt 1):6977–6985. [PubMed] [Google Scholar]
  23. Theve N. O., Pousette A., Carlström K. Adenocarcinoma of the pancreas--a hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin Oncol. 1983 Sep;9(3):193–197. [PubMed] [Google Scholar]
  24. Wong A., Chan A., Arthur K. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat Rep. 1987 Jul-Aug;71(7-8):749–750. [PubMed] [Google Scholar]
  25. Wyllie A. H. What is apoptosis? Histopathology. 1986 Sep;10(9):995–998. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES